On a year-to-date (YTD) basis, Sun Pharma stock has underperformed the Nifty Pharma index by declining around 28 per cent.
The stock rallied 8% to Rs 225 on Thursday, extending its Wednesday's 3% gain on BSE, on the expectation of strong earnings growth over the medium-term.
The domestic unit trimmed its early sharp gains to settle 8 paise higher at 70.06 on Wednesday, mainly due to dollar buying by importers in the last hour of trade.
Here's a look at the top stocks that may remain in focus in today's trading session -
Right now, the rupee and oil prices are strengthening the investment case for India with signs that the rupee's weakness has run its course and oil prices having corrected sharply, Arora says
Nifty outlook and few trading ideas by Vaishali Parekh, research analyst - technical research at Prabhudas Lilladher
Trading at IFSC has seen a gradual pick-up following easing of regulations
These receipts are being used as collateral for getting finance
Analysts cautious on sector given the inadequate profit triggers
Higher inventory levels, muted sales volumes could cap growth rates ahead
MMTC, with a shareholding of 49.9 per cent, is the biggest equity partner in the 1.1 million tonne NINL plant, where two Odisha government PSUs hold stakes.
Negotiate with the bank for better terms, or seek a moratorium
The S&P500 index had plunged 15 per cent in December
Proceeds of the issue will be utilised towards reduction of the aggregate outstanding borrowings of the company on a consolidated basis, and for general corporate purposes
Sensex revives after decline of 460 points; concerns fueled by political and economic uncertainties in America
While economic worries have weighed, the outlook is not as weak as in 2016 when a supply glut built up, because the Opec this time is trying to prop up the market
Sources say that Sebi has directed the company to withdraw prospectus or face rejection
The S&P BSE Sensex gained 180 points or 0.5 per cent to settle at 5,650 after witnessing a 700-point swing in the intraday-trade.
The benchmark indices have witnessed a 4 per cent rise so far in CY18. We take a look at some of the stocks that are likely to deliver decent returns in the coming year.
The fund inflow through P-notes in October this year was the lowest since March 2009, when the cumulative value of such investments stood at Rs 694.45 billion